Exelixis, Inc. - Common Stock (EXEL)

Exelixis Inc is a biopharmaceutical company focused on developing innovative therapies for patients with cancer

The company primarily engages in the discovery, development, and commercialization of small molecule drugs that target key pathways involved in cancer cell growth and survival. Through its research and clinical development programs, Exelixis aims to provide effective treatment options that improve patient outcomes and enhance the quality of life for individuals battling various forms of cancer. The company's commitment to oncology is evident in its robust pipeline of investigational drugs and its ongoing collaborations with other organizations in the healthcare sector.